180 related articles for article (PubMed ID: 33112290)
1. Roads to the strategic targeting of ovarian cancer treatment.
Irusta G
Reproduction; 2021 Jan; 161(1):R1-R11. PubMed ID: 33112290
[TBL] [Abstract][Full Text] [Related]
2. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
3. Convergence of Wnt and Notch signaling controls ovarian cancer cell survival.
Bocchicchio S; Tesone M; Irusta G
J Cell Physiol; 2019 Dec; 234(12):22130-22143. PubMed ID: 31087357
[TBL] [Abstract][Full Text] [Related]
4. Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer.
Chen X; Stoeck A; Lee SJ; Shih IeM; Wang MM; Wang TL
Oncotarget; 2010 Jul; 1(3):210-8. PubMed ID: 20953350
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
6. The Wnt/β-catenin pathway in ovarian cancer: a review.
Arend RC; Londoño-Joshi AI; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2013 Dec; 131(3):772-9. PubMed ID: 24125749
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of ovarian cancer including immune check point inhibitor.
Kim JY; Cho CH; Song HS
Korean J Intern Med; 2017 Sep; 32(5):798-804. PubMed ID: 28823141
[TBL] [Abstract][Full Text] [Related]
8. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.
Li B; Cai S; Zhao Y; He Q; Yu X; Cheng L; Zhang Y; Hu X; Ke M; Chen S; Zou M
Oncotarget; 2016 Dec; 7(49):81026-81048. PubMed ID: 27835587
[TBL] [Abstract][Full Text] [Related]
9. Notch signaling in serous ovarian cancer.
Groeneweg JW; Foster R; Growdon WB; Verheijen RH; Rueda BR
J Ovarian Res; 2014 Nov; 7():95. PubMed ID: 25366565
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies for Ovarian Cancer.
Grunewald T; Ledermann JA
Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
[TBL] [Abstract][Full Text] [Related]
11. Other new targets.
Mackay HJ; Oza AM
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S49-54. PubMed ID: 19955915
[TBL] [Abstract][Full Text] [Related]
12. Targeted agents in ovarian cancer.
Kristedja TS; Morgan RJ; Cristea M
Womens Health (Lond); 2010 Sep; 6(5):679-94. PubMed ID: 20887168
[TBL] [Abstract][Full Text] [Related]
13. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
14. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer.
Kaltofen T; Preinfalk V; Schwertler S; Fraungruber P; Heidegger H; Vilsmaier T; Vattai A; Czogalla B; Mayr D; Mahner S; Jeschke U; Trillsch F
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2559-2574. PubMed ID: 32681294
[TBL] [Abstract][Full Text] [Related]
15. New developments in molecular targeted therapy of ovarian cancer.
Guan LY; Lu Y
Discov Med; 2018 Nov; 26(144):219-229. PubMed ID: 30695681
[TBL] [Abstract][Full Text] [Related]
16. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
[TBL] [Abstract][Full Text] [Related]
17. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
[TBL] [Abstract][Full Text] [Related]
18. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.
Falci C; Dieci MV; Guarneri V; Soldà C; Bria E; Tortora G; Conte P
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1041-50. PubMed ID: 24953376
[TBL] [Abstract][Full Text] [Related]
20. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
Zhang C; Zhang Z; Zhang S; Wang W; Hu P
Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]